The influence of Montelukast in the treatment of patients with bronchial asthma on immune response / 中国基层医药

ABSTRACT

Objective To explore the influence of Montelukast in the treatment of patients with bronchial asthma on the immune response,and to provide the basis for clinical treatment.Methods 104 patients with bronchial asthma were selected.They were randomly divided into the treatment group and the control group by the random number table method,with 52 cases in each group.The control group patients were given conventional treatment,and the treatment group were treated with Montelukast on the basis of the control group.Daytime symptom and night symptom of the two groups before and after treatment were assessed,and airway reactivity by the early respiratory resistance (Rrsc)and response threshold (Dmin)were evaluated.And the change of T lymphocyte subsets before and after the treatment were detected.Results The day symptom scores,night symptom scores and Rrsc of the treatment group after treatment were respectively (0.49 ±0.12)points,(0.66 ±0.20)points and (2.19 ±0.38)cmH2 O,which were lower than those of the control group after treatment(t =7.90,8.13,8.24,all P <0.05).The data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.38,8.66, 9.17,9.41,8.90,9.24,all P <0.05).Dmin of the treatment group after treatment was (8.29 ±0.44)U,which was higher than that of the control group after treatment,the data of the two groups after treatment were higher than those before the treatment,the differences were statistically significant(t =7.41,8.23,all P <0.05).CD +4 and CD +4 /CD +8 of the treatment group after treatment were (43.03 ±5.02)% and(1.79 ±0.34),respectively,which were higher than those of the control group after treatment (t =9.81,10.04,all P <0.05 ).The data of the two groups after treatment were higher than those before the treatment,the differences were statistically significantly different (t =10.62,10.33,10.93,10.62,all P <0.05).CD +8 of the treatment group after treatment was (23.38 ±3.88)%, which was lower than that of the control group after treatment(t =9.93,P <0.05),the data of the two groups after treatment were lower than those before treatment,the differences were statistically significant (t =9.16,9.29,all P <0.05 ).Conclusion Montelukast treatment of bronchial asthma can significantly improve symptoms and immune function of patients,it is worthy of clinical popularization and application.